FDA warns PureChemPros over manufacturing quality failures and unapproved, misbranded hand sanitizer and hydrogen peroxide drugs.
What happened
FDA inspected PureChemPros’ drug manufacturing facility in Tempe, AZ, from November 17 to November 22, 2022, and found significant violations of current good manufacturing practice (CGMP). FDA said the firm lacked an adequate quality unit, did not test incoming components or its water, and had no stability testing to support expiration dates. FDA also reviewed product labels and the website and found the hydrogen peroxide products promoted for oral use as unapproved new drugs, plus misbranding issues on the hand sanitizer and 3% hydrogen peroxide.
What FDA found
The company did not have an adequate quality control unit to oversee manufacturing, including hand sanitizer shipped to an Amazon distribution center on September 2, 2022.
21 CFR 211.22The company did not test incoming components for identity and other specifications and relied on certificates from unqualified suppliers; it also did not test its water to show it met Purified Water USP and microbial limits.
21 CFR 211.84(d)(1) and (2)The company did not have a stability testing program to support expiration dates and based labeled expiry on the bulk active ingredient’s expiration date.
21 CFR 211.137(a)35% and 3% Food Grade Hydrogen Peroxide are unapproved new drugs because they are promoted for oral antigingivitis/antiplaque use without an FDA-approved application or applicable OTC monograph.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The same hydrogen peroxide products are misbranded because they are nonprescription drugs subject to section 505G but do not meet its requirements and lack an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)The Liquid Hand Sanitizer label lacks the manufacturer’s place of business and a domestic address or phone for serious adverse event reports, and the 3% Food Grade Hydrogen Peroxide label lacks a Drug Facts panel.
FD&C Act sections 502(b)(1), 502(x), and 502(c), 21 U.S.C. 352(b)(1), (x), and (c); 21 CFR 201.66
What FDA wants
FDA tells the company to respond in writing within 15 working days, correct violations promptly, and confirm whether it will continue manufacturing drugs; if continuing, it should engage a qualified consultant and provide a corrective action report.
Who should pay attention
- companies buying OTC hand sanitizer or hydrogen peroxide from contract manufacturers
- distributors and online marketplaces selling antiseptic drug products
- quality teams managing supplier qualification and label review
This is a summary. Read the original letter on fda.gov.